Prostate cancer gets around hormone therapy by activating a survival cell signaling pathway

Cancer is crafty. Researchers found that when a common type of prostate cancer was treated with conventional hormone ablation therapy blocking androgen production or androgen receptor (AR) function -- which drives growth of the tumor -- the cancer was able to adapt and compensate by activating a survival cell signaling pathway, effectively circumventing the roadblock put up by this treatment.

Read the whole article on Science Daily

More from Science Daily